Several new first-in-man studies for drugs targeted against a range of cancers were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
"These studies represent our first glance at some of the drugs that may improve cancer treatment in coming years," said Prof Ahmad Awada, head of the medical oncology clinic at Jules Bordet Institute, Brussels, Belgium, chair of the ESMO 2012 Developmental Therapeutics track. "Today's findings highlight the ways that clinical research is working on cancer therapies that target specific molecular pathways within tumor cells and their microenvironment. At ESMO 2012 this year, interesting early reports will be presented on MEK-, MET- and HSP90 inhibitors as well as studies on drugs targeting EGFR and PI3K and agents active in ALK-positive lung cancer resistant to crizotinib. In addition, new immunotherapeutic strategies and new generations of hormonal agents will be at the menu at this year's ESMO congress."
Key selected studies include:
A proof-of-concept study of ODM-201 in patients with progressive castration-resistant prostate cancer
In a dose-escalation trial, 87% of 15 patients who received a novel androgen receptor agonist called ODM-201 experienced a PSA decrease at 12 weeks. "These early results are very promising, and such are rarely seen in these early trials. ODM-201 might be a new hormonal treatment option, and its efficacy-safety profile seems to be very promising in prostate cancer patients," said study author Dr Christophe Massard from Institute Gustave Roussy. "Unlike other anti-androgens, according to non-clinical data, ODM-201 has minimal or no brain entrance, and thus no testosterone increase in animal models. Therefore ODM-201 could be a promising new drug option for patients with metastatic or non metastatic prostate cancer. The results need to be confirmed in bigger patient population of course."
A dose-escalation study of oral selective c-Met inhibitor EMD 1214063 in patients with advanced solid tumors
The cell surface receptor tyrosine kinase c-Met is an emerging target for cancer treatment. EMD 1214063 is a highly selective, reversible and ATP-competitive c-Met inhibitor that causes growth inhibition and regression of HGF-dependent and HGF-independent tumors in pre-clinical models. This dose-escalation study is ongoing, with some preliminary evidence of clinical response being seen.
Multicenter study of the investigational drug TAK-733, an oral MEK inhibitor
Preliminary data of this trial in patients with advanced solid tumors indicate that TAK-733 is generally well tolerated and pharmacodynamically active with signs of anti-tumor activity in patients with advanced non-hematologic malignancies, say researchers.
Phase II study of HSP90 inhibitor AUY922 in patients with ALK-rearranged or EGFR-mutated advanced lung cancer
Among 121 patients with previously treated non-small cell lung cancer, activity was demonstrated in both ALK+ and EGFR-mutant patients, say investigators. Overall tumor response and progression-free survival rates observed warrant further studies, particularly among EGFR-mutant patients.Results of a first-in-human study of the ALK inhibitor LDK378 in advanced solid tumors
ESMO PERSS OFFICE | EurekAlert!
NIST scientists discover how to switch liver cancer cell growth from 2-D to 3-D structures
17.11.2017 | National Institute of Standards and Technology (NIST)
High speed video recording precisely measures blood cell velocity
15.11.2017 | ITMO University
The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.
Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...
Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.
That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...
Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.
During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....
The quantum world is fragile; error correction codes are needed to protect the information stored in a quantum object from the deteriorating effects of noise. Quantum physicists in Innsbruck have developed a protocol to pass quantum information between differently encoded building blocks of a future quantum computer, such as processors and memories. Scientists may use this protocol in the future to build a data bus for quantum computers. The researchers have published their work in the journal Nature Communications.
Future quantum computers will be able to solve problems where conventional computers fail today. We are still far away from any large-scale implementation,...
Pillared graphene would transfer heat better if the theoretical material had a few asymmetric junctions that caused wrinkles, according to Rice University...
15.11.2017 | Event News
15.11.2017 | Event News
30.10.2017 | Event News
17.11.2017 | Physics and Astronomy
17.11.2017 | Health and Medicine
17.11.2017 | Studies and Analyses